Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocksGLENMARK
resources
GLENMARK

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK
BSE: 532296
Sector: Healthcare
Industry: Pharmaceuticals
2,129.60-68.9 (-3.13%)
23 Oct, 12:00 AM

Annual Reports and Financial Documents

Glenmark Pharmaceuticals Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

Corporate Announcements and Regulatory Filings

Glenmark Pharmaceuticals Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.
  1. Analyst / Investor Meet23 Oct 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of Earnings Call
  2. Board Meeting23 Oct 2026
    Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of Glenmark Pharmaceuticals Limited ('The Company') For The Quarter And Half Year Ended September 30, 2026
    Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial ....
  3. Press Release / Media Release6 Oct 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)
  4. Closure of Trading Window28 Sept 2026
    Closure of Trading Window
    Intimation for closure of trading window for second quarter of FY 2026-27
  5. Press Release / Media Release23 Sept 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification
  6. Analyst / Investor Meet21 Sept 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst/ Institutional Investor Meetings
  7. AGM11 Sept 2026
    Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
    Report of Scrutinizer is enclosed
  8. AGM11 Sept 2026
    Shareholder Meeting / Postal Ballot-Outcome of AGM
    Proceedings of the 48th AGM of the Company is enclosed
  9. Press Release / Media Release11 Sept 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark expands Global Respiratory Innovation Footprint with RYALTRIS launch in Brazil
  10. Credit Rating11 Sept 2026
    Announcement under Regulation 30 (LODR)-Credit Rating
    Please find enclosed rating rationale issued by India Ratings and Research
  11. Press Release / Media Release21 Aug 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....
  12. Press Release / Media Release20 Aug 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray
  13. Newspaper Publication15 Aug 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Newspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday, September 11, 2026 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")
  14. General13 Aug 2026
    Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report
    Letter to Shareholders whose email address are not registered providing the web link of Annual Report
  15. Business Responsibility and Sustainability Reporting (BRSR)13 Aug 2026
    Business Responsibility and Sustainability Reporting (BRSR)
    Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26
  16. Reg. 34 (1) Annual Report13 Aug 2026
    Reg. 34 (1) Annual Report.
    Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.
  17. AGM13 Aug 2026
    Notice Of The 48Th Annual General Meeting For The Financial Year 2025-26
    Please find attached Notice of 48th Annual General Meeting for the Financial Year 2025-26
  18. General11 Aug 2026
    Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
    Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
  19. Allotment of ESOP / ESPS10 Aug 2026
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
    Intimation of Allotment of shares under the Employee Stock Option Plan 2016
  20. Analyst / Investor Meet7 Aug 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of Schedule of Analyst / Institutional Investor Meetings

Frequently Asked Questions

Where can I download the annual report of Glenmark Pharmaceuticals Ltd.?
Annual reports of Glenmark Pharmaceuticals Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.
Where can I find the quarterly results of Glenmark Pharmaceuticals Ltd.?
Quarterly earnings results and presentations of Glenmark Pharmaceuticals Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.
Does Glenmark Pharmaceuticals Ltd. publish earnings call transcripts?
Earnings call transcripts of Glenmark Pharmaceuticals Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.
Where can I find investor presentations of Glenmark Pharmaceuticals Ltd.?
Investor presentations and annual day presentations of Glenmark Pharmaceuticals Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.
What are the recent corporate announcements of Glenmark Pharmaceuticals Ltd.?
Corporate announcements and regulatory filings of Glenmark Pharmaceuticals Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.
How do I access the regulatory filings of Glenmark Pharmaceuticals Ltd.?
Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Glenmark Pharmaceuticals Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.
What is the ISIN of Glenmark Pharmaceuticals Ltd.?
The ISIN (International Securities Identification Number) of Glenmark Pharmaceuticals Ltd. is INE935A01035. This is the unique identifier used across exchanges and depositories.
On which stock exchange is Glenmark Pharmaceuticals Ltd. listed?
Glenmark Pharmaceuticals Ltd. is listed on NSE and BSE. The NSE symbol is GLENMARK and the BSE code is -.
Where can I find the shareholding pattern of Glenmark Pharmaceuticals Ltd.?
The quarterly shareholding pattern of Glenmark Pharmaceuticals Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.
How current is the data for Glenmark Pharmaceuticals Ltd. on Sharpely?
Share price data for Glenmark Pharmaceuticals Ltd. is updated as of 23 Oct 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.